Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q15131

UPID:
CDK10_HUMAN

ALTERNATIVE NAMES:
Cell division protein kinase 10; Serine/threonine-protein kinase PISSLRE

ALTERNATIVE UPACC:
Q15131; A8K370; A8K8I6; A8MXU6; B3KQJ3; B7Z420; D3DX82; D3DX83; Q0VGZ7; Q15130; Q6PJC0

BACKGROUND:
The protein Cyclin-dependent kinase 10, with alternative names Cell division protein kinase 10 and Serine/threonine-protein kinase PISSLRE, is instrumental in cellular processes such as ETS2 transcription factor phosphorylation and actin cytoskeleton organization. It acts as a negative regulator of ciliogenesis by phosphorylating PKN2 and enhancing RhoA signaling pathways.

THERAPEUTIC SIGNIFICANCE:
Involvement of CDK10 in Al Kaissi syndrome, characterized by developmental and physical abnormalities, underscores its potential as a target for therapeutic intervention. Understanding the role of CDK10 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.